Serendia v. Lutronic Aesthetics: Six-Patent Skin Treatment Dispute Voluntarily Dismissed
Serendia LLC filed suit in the District of Delaware against Lutronic Aesthetics asserting six patents covering electrically based dermatological treatment devices and methods. The case ended 327 days later when Serendia voluntarily dismissed before Lutronic filed any answer, with each party bearing its own costs.
Six-Patent Dermatology Dispute Ends Before First Answer in Delaware
On March 1, 2023, Serendia LLC filed a patent infringement action against Lutronic Aesthetics, Inc. in the District of Delaware (Case No. 1:23-cv-00225), before Chief Judge Richard G. Andrews. Serendia asserted six U.S. patents — US11406444B2, US9775774B2, US10058379B2, US9320536B2, US9480836B2, and US10869812B2 — covering electrically based medical treatment devices, dermatological treatment systems, and skin treatment apparatus and methods.
On January 22, 2024, Serendia filed a Notice of Voluntary Dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), which permits a plaintiff to dismiss an action without a court order if the defendant has not yet served an answer or a motion for summary judgment. Lutronic Aesthetics had not answered the complaint, making the dismissal self-executing. The notice specified that each party would bear its own costs, expenses, and attorneys’ fees — a notably neutral cost allocation.
The 327-day gap between filing and voluntary dismissal, combined with the pre-answer timing and mutual cost-bearing terms, is consistent with a confidential commercial resolution reached between the parties — though the public record is silent on any such agreement. The case never reached claim construction, discovery, or substantive merits adjudication. Whether Serendia obtained a license, covenants not to sue, or any other commercial consideration from Lutronic Aesthetics cannot be confirmed from the docket alone.
Filing to resolution in 327 days
327 days — resolved before defendant’s answer was filed, suggesting early commercial resolution
Voluntarily dismissed: what Rule 41(a)(1)(A)(i) means for both parties
Rule 41(a)(1)(A)(i): dismissal without court order
Federal Rule of Civil Procedure 41(a)(1)(A)(i) allows a plaintiff to dismiss a case unilaterally — without the court’s permission — at any time before the defendant serves an answer or motion for summary judgment. Because Lutronic Aesthetics had not yet answered, Serendia’s notice was self-executing and took immediate effect. No judicial merits determination was made.
Pre-answer voluntary dismissalWith or without prejudice? The public record is silent
A Rule 41(a)(1)(A)(i) dismissal is presumed without prejudice under the Federal Rules unless the notice expressly states otherwise. Serendia’s notice does not specify either way. This distinction matters: a without-prejudice dismissal preserves Serendia’s right to refile; a with-prejudice dismissal would extinguish those claims permanently. Practitioners should not assume either outcome — the docket does not resolve the question.
Prejudice status unconfirmedSerendia retains its patent portfolio intact
Voluntary dismissal leaves all six asserted patents in force and unencumbered by any adverse merits ruling. No claims were invalidated or found non-infringed. If the dismissal is without prejudice — the default rule — Serendia could refile against Lutronic or assert the same patents against other parties in the aesthetic device sector.
Patents survive, rights preservedLutronic exits without admissions — but uncertainty remains
Lutronic Aesthetics avoided a merits adjudication and incurs no liability or injunction from this proceeding. The mutual cost-bearing term means no fee award either way. However, without a covenant not to sue or license on the public record, Lutronic’s FTO position against Serendia’s six-patent portfolio remains formally unresolved. Monitoring Serendia’s future enforcement activity is advisable.
No admission of infringementFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Serendia, LLC | Company | Medical device IP holding entity — holder of US11406444B2 and five dermatology treatment patentsSearch in Eureka ↗ |
| Defendant | Lutronic Aesthetics, Inc. | Company | Lutronic Aesthetics, Inc. — developer and marketer of energy-based aesthetic treatment devicesSearch in Eureka ↗ |
| Plaintiff counsel | Cecilia Sanabria | Attorney | Counsel for Serendia, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Sanders | Attorney | Counsel for Serendia, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kevin C. Wheeler | Attorney | Counsel for Serendia, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Timothy Devlin | Attorney | Counsel for Serendia, LLCSearch in Eureka ↗ |
| Defendant counsel | David E. Moore | Attorney | Counsel for Lutronic Aesthetics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) precisely and confirms that Lutronic had not yet answered — making the dismissal self-executing and requiring no judicial sign-off. The explicit mutual cost-bearing clause is notable: it departs from the default ‘costs to plaintiff’ expectation in unilateral dismissals and suggests the parties negotiated the exit terms. No merits findings, claim constructions, or invalidity rulings attach to this dismissal.
US11406444B2 — Electrically Based Medical Treatment Device and Method
The six asserted patents span three product and method categories: electrically based medical treatment devices (US11406444B2, US10869812B2), dermatological treatment methods and systems (US9775774B2, US10058379B2), and skin treatment apparatus and methods (US9320536B2, US9480836B2). The application numbers span filings from US13/825083 through US17/061523 — a range consistent with a continuation family prosecuted over roughly a decade, allowing claim scope to evolve alongside commercial device development in the aesthetic energy-based treatment sector.
A portfolio covering device architecture, system-level methods, and treatment apparatus across multiple continuation generations creates layered enforcement risk for competitors. Each continuation patent in a family can carry independent claim sets targeting different aspects of a commercial product, meaning a single device may face infringement exposure on several fronts simultaneously. For companies developing RF-based, laser, or other energy-based dermatological platforms, the breadth of this assertion — six patents across three product categories — signals that Serendia’s IP strategy is designed to achieve maximum coverage across the aesthetics treatment workflow.
Should your R&D team run an FTO against Serendia’s dermatology patent portfolio?
Any company designing, manufacturing, or commercialising electrically based medical treatment devices, energy-based skin treatment systems, or dermatological treatment apparatus should treat this case as a prompt to review their FTO position against all six Serendia patents. The portfolio’s continuation structure means infringement exposure may arise even from design changes intended to design around earlier grants. Device OEMs, contract manufacturers, and distributors in the aesthetic treatment market are all potentially within scope.
PatSnap Eureka’s FTO Search Agent enables systematic claim-level mapping across all six patents in the Serendia portfolio simultaneously. Eureka can identify prior art, flag claim language with the broadest potential read-on risk, and surface any pending continuation applications that may extend the enforcement window. For R&D teams evaluating next-generation device architectures, running an Eureka FTO analysis before design lock-in significantly reduces downstream litigation exposure.
Run a freedom-to-operate analysis on US11406444B2 to assess your product’s exposure
Run FTO in Eureka →Similar Dermatological Device Patent Cases in Delaware District Court
Cases involving electrically based skin treatment and energy-based aesthetics patents litigated in the District of Delaware, including comparable multi-patent assertion campaigns.
What this case signals for the aesthetic medical device IP landscape
Six asserted patents, zero merits rulings, and a mutual cost split: the dismissal pattern here warrants close reading by IP teams in the energy-based aesthetics sector.
Pre-answer dismissals with mutual cost splits often signal commercial resolution
When a plaintiff voluntarily dismisses before the defendant answers and both parties agree to bear their own costs, the pattern is consistent with a private settlement — whether a license, covenant not to sue, or commercial arrangement. IP teams at competitors in the aesthetics device market should treat this as a signal that Serendia’s portfolio may be actively monetised.
Six-patent assertion portfolios in aesthetics demand systematic FTO review
Serendia’s assertion of six patents spanning device architecture, method steps, and system-level claims across different application families signals a broad enforcement posture. Companies developing electrically based or energy-based dermatological treatment devices should conduct claim-level FTO analysis across the entire Serendia portfolio, not just the lead patent.
Serendia v Lutronic — key questions answered
Serendia LLC filed a six-patent infringement action against Lutronic Aesthetics in the District of Delaware on March 1, 2023. On January 22, 2024, Serendia voluntarily dismissed the case under Rule 41(a)(1)(A)(i) before Lutronic filed an answer. Each party agreed to bear its own costs. No merits rulings were issued.
Serendia asserted six U.S. patents: US11406444B2, US9775774B2, US10058379B2, US9320536B2, US9480836B2, and US10869812B2. The patents cover electrically based medical treatment devices, dermatological treatment methods and systems, and skin treatment apparatus and methods.
The dismissal notice does not specify. Under Federal Rule of Civil Procedure 41(a)(1)(A)(i), a voluntary dismissal before the defendant answers is presumed without prejudice unless the notice states otherwise. Serendia’s notice is silent on this point, leaving the prejudice question formally unresolved on the public docket.
The notice expressly states each party bears its own costs, expenses, and attorneys’ fees. This mutual cost allocation, combined with the pre-answer timing, is consistent with — though does not confirm — a private commercial resolution such as a license or covenant not to sue. The public record does not disclose any such agreement.
Yes. A voluntary dismissal does not invalidate, limit, or impose any adverse ruling on the asserted patents. All six patents remain in force with their original claim scope intact. Serendia retains the right to assert them against other parties in the aesthetic device market, and potentially against Lutronic again if the dismissal was without prejudice.
PatSnap Eureka searches patents and litigation data to answer instantly.